Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study-Reference-Cited by-同舟云学术

Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study

Published:2024-08-09 Issue:1 Volume:23 Page:
ISSN:1476-4598
Container-title:Molecular Cancer
language:en
Short-container-title:Mol Cancer

Author:

Li Jin,Liu Jihong,Yin Rutie,Zou Dongling,Zheng Hong,Cao Junning,Chen Zhendong,Sun Wei,Gao Yunong,Zhang Songling,Zeng Linjuan,An Ruifang,Lu Xianping,Ye Shuang,Wu Xiaohua

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12943-024-02076-x.pdf

Reference15 articles.

1. NCCN clinical practice guidence in ovarian cancer/fallopian tube cancer/pimary peritoneal cancer (2024 Version 2.0). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453.

2. Friedlander M, Hancock K, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119(1):32–7.https://doi.org/10.1016/j.ygyno.2010.05.033.

3. Matei D, Sill M, Lankes H, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol. 2011;29(1):69–75. https://doi.org/10.1200/jco.2009.26.7856.

4. Cannistra S, Matulonis U, Penson R, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180–6. https://doi.org/10.1200/jco.2007.12.0782.

5. Y Ma, H Cao, Lou, SiyueShao, et al. Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc. J Mol Med (Berl). 2015;93(4):427–38. https://doi.org/10.1007/s00109-014-1228-0.